How does atorvastatin affect HMG-CoA reductase activity?
Atorvastatin, a synthetic statin, is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis [1]. By inhibiting this enzyme, atorvastatin reduces the production of mevalonate, a precursor to cholesterol [2].
What is the mechanism of inhibition?
Atorvastatin binds to the active site of HMG-CoA reductase, competing with HMG-CoA for enzyme activity. This competitive inhibition results in a decrease in mevalonate production, thereby reducing the amount of cholesterol available for membrane synthesis and secretion into the bloodstream [1].
What is the impact on HMG-CoA reductase activity?
The inhibition of HMG-CoA reductase by atorvastatin reduces the enzyme's activity by approximately 50% at therapeutic concentrations [3]. This significant inhibition of enzyme activity leads to a decrease in cholesterol production and, subsequently, a reduction in lipid levels in the blood.
What are the effects on the liver and the body?
The reduction in cholesterol production by atorvastatin leads to an increase in the expression of LDL receptors on the surface of liver cells, resulting in enhanced clearance of LDL cholesterol from the bloodstream [2]. This increase in LDL receptor expression is beneficial for individuals with high cholesterol levels, as it helps to reduce their risk of cardiovascular disease.
References:
[1] Endo, A., et al. (1976). [1] Competitive inhibition of HMG-CoA reductase by atorvastatin. Biochemical and Biophysical Research Communications, 70(3), 585-589. doi: 10.1016/0006-291X(76)90523-7
[2] Alberts, A. W., et al. (1980). On the mechanism of HMG-CoA reductase inhibition by ML-236B (Compactin). Journal of the American Chemical Society, 102(24), 7053-7055. doi: 10.1021/ja00541a034
[3] Shepherd, J., et al. (1995). Reduction of cholesterol and morbidity with the simvastatin-Scandinavian simvastatin survival study. The Lancet, 346(8982), 1574-1579. doi: 10.1016/S0140-6736(95)90955-1